China
Africa
Explore chapters and articles related to this topic
Order Picornavirales
Published in Paul Pumpens, Peter Pushko, Philippe Le Mercier, Virus-Like Particles, 2022
Paul Pumpens, Peter Pushko, Philippe Le Mercier
At last, Diamos and Mason HS (2018) elaborated a plant-based recombinant protein expression system based on agroinfiltration of a replicating vector derived from the geminivirus bean yellow dwarf virus (BeYDV) and achieved and produced in N. benthamiana the NoV GII.4 VLPs at >1 mg/g leaf fresh weight, over three times the highest level ever reported in plant-based systems.
Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease
Published in Expert Review of Vaccines, 2021
Abel Ramos-Vega, Elizabeth Monreal-Escalante, Eric Dumonteil, Bernardo Bañuelos-Hernández, Carlos Angulo
On the other hand, the biological methods for transformation include mainly two: (1) agroinfiltration and (2) magnifection using viral vectors. Currently, Agrobacterium-mediated transformation is the most popular method to achieve this modification since it has advantages, which include transfer of DNA pieces with defined ends and minimal genetic rearrangement; transfer of relatively large DNA segments; integration of small numbers of gene copies into plant chromosomes; and high quality and fertility of both monocotyledonous and dicotyledonous transgenic plants. Stable inheritance and transgene expression in the progeny have also been demonstrated [71]. However, the transgene is nonspecifically inserted into the genome, which may cause the silencing mechanism induction that dampers high productivity. The Agrobacterium-mediated delivery of viral vectors has consolidated as a highly efficient strategy to achieve rapid production of heterologous protein in plants. This concept has been further applied to biopharmaceutical and vaccine production [73].
Production of active human FGF21 using tobacco mosaic virus-based transient expression system
Published in Growth Factors, 2021
Jieying Fan, Yunpeng Wang, Shuang Huang, Shaochen Xing, Zhengyi Wei
The TMV-TES platform has already been used for the expression of various vaccines, antibodies, and other therapeutic proteins. This platform is regarded as the core technology by some medical companies and their products have been approved for clinical trials or even commercial production (Huang et al. 2019). Additionally, potato virus X (PVX)-based vector, fused with the sequence encoding the human FGF21 gene, was introduced into leaf cells of tobacco via Agrobacterium-mediated agroinfiltration, and the purified rhFGF21 was biologically active and stimulated glucose uptake in 3T3/L1 cells (Fu et al. 2011). To our knowledge, there has been no report for the transient expression of recombinant FGF21 based on TMV vectors. The present study optimised the parameters of the TMV-TES to express FGF21 with biological activity.
The potential of plant-made vaccines to fight picornavirus
Published in Expert Review of Vaccines, 2020
Omayra C. Bolaños-Martínez, Sergio Rosales-Mendoza
The potential of plant-based platforms to generate new products in the clinic is real and evidenced by the approval of Elelyso® (Protalix Bio Therapeutics, Karmiel, Israel, which is a plant-made version of the glucocerebrosidase used as replacement therapy for Gaucher’s disease. This target is expressed in carrot cells using bioreactors and purified to be administered parenterally to patients. Besides attractive costs, this plant-based system confers an appropriate glycans pattern to the biopharmaceutical; since the enzyme expressed in mammalian cells possess terminal sialic acid, galactose, and N-acetylglucosamine residues on the glycans chains that inhibit the mannose receptors-mediated endocytosis by macrophages. In contrast, the carrot-made enzyme lacks sialic acid and targeting it to the vacuole prevents the extension of terminal mannose residues, which results in an enzyme that is efficiently captured by macrophages [9]. Another remarkable example on the potential of plant-made biopharmaceuticals is ZMapp™ (developed by Leaf Biopharmaceutical, San Diego, CA, USA), which consists of a cocktail of three monoclonal antibodies to treat Ebola. This product is obtained in transiently transformed N. benthamiana plants and it has been approved for its use before completion of clinical testing during an outbreak of the viral disease in West Africa. Seven patients were treated with the available ZMapp stock and five of them ultimately recovered. At present, ZMapp is under clinical evaluations [10]. A final example are the influenza vaccines developed by Medicago (Québec, Canada/Durham, NC, USA), which are based on agroinfiltration of the N. benthamiana plants for the production of virus-like particles (VLPs) as vaccine candidates. Their products include the human quadrivalent seasonal influenza that has already completed phase II and phase III clinical trials, the pandemic influenza with the phase II clinical trial finished, the rotavirus vaccine with the phase I clinical trial complete, and norovirus with preclinical studies accomplished [11].